Welcome to our dedicated page for Longevity Health news (Ticker: XAGEW), a resource for investors and traders seeking the latest updates and insights on Longevity Health stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Longevity Health's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Longevity Health's position in the market.
Longevity Health Holdings (NASDAQ: XAGE) has successfully completed an at-the-market (ATM) equity offering, selling 479,621 shares at an average price of $4.08 per share, raising gross proceeds of $1.96 million. The funding is expected to extend the company's cash runway into Q1 FY26, based on FY24 pro forma consolidated sales projections. The financing comes as XAGE prepares for its planned merger with 20/20 while continuing to focus on its longevity products business.
Longevity Health Holdings (NASDAQ: XAGE) announced several key business updates. The company has entered into a merger agreement with 20/20 BioLabs on April 11, 2025, with an S-4 prospectus filed on May 8. Q1 unaudited sales showed growth for both companies: XAGE reported $663,000 (+8% YoY) while 20/20 achieved $562,000 (+15% YoY).
The company completed a 1-for-30 reverse stock split on May 12, 2025. Both companies plan Q2 product launches: XAGE will introduce a medicated cleanser for medical professionals, while 20/20 will launch a blood inflammatory biomarker test. Additionally, 20/20 initiated a pilot program with Giant Food for their OneTest™ multi-cancer test at 9 stores in Maryland and Virginia. XAGE is exploring additional financing options for Q2 2025.
Longevity Health Holdings (NASDAQ: XAGE) has announced a 1-for-30 reverse stock split effective May 12, 2025. The split will reduce outstanding shares from approximately 30.1 million to 1 million. Trading on the split-adjusted basis will begin on the Nasdaq Capital Market on May 14, 2025, under the same ticker symbol "XAGE".
The reverse split was approved by stockholders on March 24, 2025. Fractional shares will be rounded up to the nearest whole share. No stockholder action is required for those holding shares electronically or in street name. Proportional adjustments will be made to outstanding stock options, warrants, and shares under the 2023 Equity Incentive Plan.
Longevity Health Holdings (NASDAQ: XAGE) has announced a merger agreement with 20/20 BioLabs in an all-stock transaction valued at approximately $99 million. The merger is expected to double Longevity's fiscal year 2025 revenue from $3-4 million to $7-8 million, with anticipated operational savings of over $1 million.
20/20 BioLabs operates a CLIA Licensed, CAP Accredited lab and offers OneTest™, a multi-cancer early detection blood test for over a dozen tumor types at under $200. The company has integrated its testing into routine evaluations for firefighters and military veterans, and plans to launch a longevity test in Spring 2025.
Post-merger, the combined company will continue trading under XAGE, with Jonathan Cohen appointed as CEO while Rajiv Shukla remains Chairman. The merger advances Longevity's strategy in diagnostics and synergizes with its bio-aesthetic portfolio under the banner "Healthy Aging, Inside and Out™".
FAQ
What is the current stock price of Longevity Health (XAGEW)?
